HC Wainwright Has Optimistic Outlook of ETON Q2 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – HC Wainwright raised their Q2 2025 earnings per share estimates for shares of Eton Pharmaceuticals in a note issued to investors on Monday, January 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.08 per share for the quarter, up from their previous estimate of $0.07. HC Wainwright has a “Buy” rating and a $17.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2025 earnings at $0.38 EPS and FY2026 earnings at $0.84 EPS.

Separately, Craig Hallum upped their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday.

Eton Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ:ETON opened at $12.01 on Thursday. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $15.00. The company has a market capitalization of $312.87 million, a price-to-earnings ratio of -54.59 and a beta of 1.38. The firm’s 50-day moving average is $11.57 and its 200 day moving average is $7.32.

Institutional Trading of Eton Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Thompson Siegel & Walmsley LLC bought a new position in Eton Pharmaceuticals during the 2nd quarter worth about $420,000. Renaissance Technologies LLC boosted its stake in shares of Eton Pharmaceuticals by 63.8% during the second quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after purchasing an additional 41,469 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in Eton Pharmaceuticals during the second quarter valued at approximately $3,095,000. Stonepine Capital Management LLC bought a new position in Eton Pharmaceuticals in the second quarter worth approximately $362,000. Finally, Aristides Capital LLC bought a new position in Eton Pharmaceuticals in the second quarter worth approximately $658,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.